W. Sandrock Alfred's most recent trade in Voyager Therapeutics Inc was a trade of 10,885 Common Stock done at an average price of $3.4 . Disclosure was reported to the exchange on April 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 02 Apr 2025 | 10,885 | 430,931 (1%) | 0% | 3.4 | 37,336 | Common Stock |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 290,000 | 290,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 145,000 | 441,816 (1%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.24 per share. | 20 Feb 2025 | 11,702 | 296,816 (0%) | 0% | 4.2 | 49,616 | Common Stock |
| Voyager Therapeutics Inc | Alfred W. Sandrock | President & CEO | Sale of securities on an exchange or to another person at price $ 4.45 per share. | 11 Feb 2025 | 16,644 | 308,518 (0%) | 0% | 4.5 | 74,066 | Common Stock |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 02 Apr 2024 | 12,115 | 322,839 (0%) | 0% | 9.9 | 119,454 | Common Stock |
| Voyager Therapeutics Inc | W. Alfred Sandrock | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.46 per share. | 21 Feb 2024 | 13,033 | 334,954 (0%) | 0% | 7.5 | 97,226 | Common Stock |
| Voyager Therapeutics Inc | W. Sandrock Alfred | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 260,000 | 260,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2024 | 130,000 | 347,987 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.83 per share. | 03 Apr 2023 | 7,437 | 214,618 (0%) | 0% | 7.8 | 58,232 | Common Stock |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 240,000 | 240,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 120,000 | 222,055 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 940,600 | 940,600 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Mar 2022 | 100,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Voyager Therapeutics Inc | Alfred W. Sandrock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2022 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Biogen | Alfred W. Sandrock | Head of Research & Development | Sale of securities on an exchange or to another person at price $ 440.00 per share. | 07 Jun 2021 | 7,672 | 10,169 (0%) | 0% | 440 | 3,375,680 | Common Stock |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 14,500 | 14,500 | - | - | Restricted Stock Unit | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 2,310 | 8,042 | - | - | Restricted Stock Unit | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 1,996 | 3,446 | - | - | Restricted Stock Unit | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,708 | 19,715 (0%) | 0% | 0 | Common Stock | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,708 | 10,352 | - | - | Restricted Stock Unit | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 1,533 | 15,261 (0%) | 0% | 278.0 | 426,220 | Common Stock |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 1,466 | 0 | - | - | Restricted Stock Unit | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,446 | 18,007 (0%) | 0% | 0 | Common Stock | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,446 | 5,442 | - | - | Restricted Stock Unit | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,300 | 16,561 (0%) | 0% | 0 | Common Stock | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 1,300 | 1,466 | - | - | Restricted Stock Unit | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 758 | 17,738 (0%) | 0% | 278.0 | 210,747 | Common Stock |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 642 | 18,496 (0%) | 0% | 278.0 | 178,495 | Common Stock |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 577 | 19,138 (0%) | 0% | 278.0 | 160,423 | Common Stock |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 3,728 | 16,794 (0%) | 0% | 0 | Common Stock | |
| Biogen | Alfred W. Sandrock | EVP, Research & Development | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 04 Nov 2020 | 1,500 | 13,066 (0%) | 0% | 350 | 525,000 | Common Stock |